DCT and melanoma: Next, we tested the PeptiBAC platform in a syngeneic mouse model of B16.F10.9/K1 melanoma using a more relevant, tumor-associated antigen from tyrosinase-related protein 2 (Trp2180–188) in combination with anti-PD-1 ICI therapy.